Related Experiment Videos
Tolerability and quality of life in ARB-treated patients
Insights
Angiotensin receptor blockers (ARBs) are well-tolerated antihypertensive agents, showing fewer side effects like cough and angioedema compared to ACE inhibitors. ARBs also improve patient quality of life, enhancing treatment adherence.
Area of Science:
- Pharmacology
- Clinical Medicine
- Cardiovascular Research
Background:
- Antihypertensive medication side effects can reduce patient adherence.
- Patient-reported outcomes, including quality of life (QOL), are crucial for treatment success.
Purpose of the Study:
- To evaluate the tolerability and side effect profile of angiotensin receptor blockers (ARBs).
- To assess the impact of ARBs on patient quality of life (QOL) and treatment adherence.
Main Methods:
- Analysis of controlled clinical trials involving over 11,000 patients.
- Comparison of adverse event frequencies between ARBs and angiotensin-converting enzyme inhibitors (ACEIs).
- Evaluation of QOL measures in patients treated with ARBs.
Main Results:
- ARBs are generally well tolerated, with mild to moderate adverse effects (headache, dizziness, nausea, diarrhea).
- Significantly lower incidence of cough with ARBs compared to ACEIs.
- Lower frequency of angioedema with ARBs versus ACEIs, though cross-reactivity is possible.
- Studies indicate improved QOL in patients switched to ARBs from other antihypertensives.
Conclusions:
- ARBs offer a favorable tolerability profile for managing hypertension.
- Reduced side effect burden and improved QOL associated with ARBs can enhance patient adherence to antihypertensive therapy.
Abstract:
Side effects associated with some antihypertensive agents can adversely affect patient adherence to a treatment regimen. Controlled clinical trials involving >11,000 patients have consistently shown that the angiotensin receptor blockers (ARBs) are generally well tolerated. Adverse effects, such as headache, lightheadedness, dizziness, nausea, and diarrhea, have been described as mild to moderate. The frequency of cough is significantly lower in patients treated with ARBs than in those receiving angiotensin-converting enzyme inhibitors (ACEIs). Angioedema, a less common but more serious side effect, also appears to be seen less frequent with ARBs than with ACEIs, although cross-reactivity is possible. Quality of life (QOL) is another important factor affecting treatment adherence. Recent studies have shown improvements in QOL measures in patients switched from other classes of antihypertensive agents to ARBs.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:28Drug Therapy
Antianxiety Medications